Ionis Pharmaceuticals Inc (IONS)
33.94
-1.46
(-4.11%)
USD |
NASDAQ |
Nov 21, 16:00
33.94
0.00 (0.00%)
After-Hours: 20:00
Ionis Pharmaceuticals Enterprise Value: 4.385B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 4.385B |
| November 19, 2024 | 4.124B |
| November 18, 2024 | 4.121B |
| November 15, 2024 | 4.217B |
| November 14, 2024 | 4.674B |
| November 13, 2024 | 4.760B |
| November 12, 2024 | 4.759B |
| November 11, 2024 | 4.934B |
| November 08, 2024 | 4.983B |
| November 07, 2024 | 4.868B |
| November 06, 2024 | 4.959B |
| November 05, 2024 | 4.921B |
| November 04, 2024 | 4.865B |
| November 01, 2024 | 4.915B |
| October 31, 2024 | 4.857B |
| October 30, 2024 | 4.991B |
| October 29, 2024 | 5.062B |
| October 28, 2024 | 5.164B |
| October 25, 2024 | 4.980B |
| October 24, 2024 | 4.913B |
| October 23, 2024 | 4.858B |
| October 22, 2024 | 4.899B |
| October 21, 2024 | 4.950B |
| October 18, 2024 | 5.057B |
| October 17, 2024 | 4.869B |
| Date | Value |
|---|---|
| October 16, 2024 | 4.975B |
| October 15, 2024 | 4.767B |
| October 14, 2024 | 4.891B |
| October 11, 2024 | 4.861B |
| October 10, 2024 | 4.784B |
| October 09, 2024 | 4.801B |
| October 08, 2024 | 4.760B |
| October 07, 2024 | 4.770B |
| October 04, 2024 | 4.778B |
| October 03, 2024 | 4.762B |
| October 02, 2024 | 5.010B |
| October 01, 2024 | 4.961B |
| September 30, 2024 | 5.117B |
| September 27, 2024 | 5.641B |
| September 26, 2024 | 5.680B |
| September 25, 2024 | 5.663B |
| September 24, 2024 | 5.664B |
| September 23, 2024 | 5.795B |
| September 20, 2024 | 5.942B |
| September 19, 2024 | 5.939B |
| September 18, 2024 | 5.879B |
| September 17, 2024 | 5.745B |
| September 16, 2024 | 5.617B |
| September 13, 2024 | 5.852B |
| September 12, 2024 | 5.667B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.911B
Minimum
Dec 01 2021
7.969B
Maximum
Jan 25 2021
5.284B
Average
5.133B
Median
Enterprise Value Benchmarks
| Biogen Inc | 27.33B |
| Alnylam Pharmaceuticals Inc | 30.33B |
| Biomarin Pharmaceutical Inc | 11.59B |
| Amicus Therapeutics Inc | 3.005B |
| Arbutus Biopharma Corp | 524.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -140.48M |
| Revenue (Quarterly) | 133.81M |
| Total Expenses (Quarterly) | 282.43M |
| EPS Diluted (Quarterly) | -0.95 |
| Gross Profit Margin (Quarterly) | 99.20% |
| Profit Margin (Quarterly) | -105.0% |
| Earnings Yield | -7.19% |
| Normalized Earnings Yield | -8.933 |